Australia Set to Combat RSV with New Vaccine | |
Australia has recently approved the use of a new protein-based vaccine named AREXVY by GlaxoSmithKline (GSK) for preventing lower respiratory tract disease caused by Respiratory Syncytial Virus (RSV). This approval, granted by the Therapeutic Goods Administration (TGA), marks a significant advancement in healthcare for individuals aged 60 and above. The vaccine will be available through private prescriptions, and its development is particularly crucial as older Australians are vulnerable to severe RSV infections. RSV infections can be especially severe among specific age groups, with symptoms varying depending on age. While the very young and the old are more susceptible to severe RSV infections, older adults, particularly those over 60, are at higher risk of getting infected. These infections can lead to serious complications, especially for individuals with chronic lung disease, heart disease, or compromised immune systems. Hospitalizations and deaths from respiratory syncytial virus are not uncommon among older Australians, making the development of an effective vaccine a significant step forward in addressing this health concern. For more details please visit our website - https://www.medhealthinsight.com/australia-set-to-combat-rsv-with-new-vaccine/ ![]() | |
Related Link: Click here to visit item owner's website (0 hit) | |
Target State: New York Target City : New York City Last Update : Jul 28, 2025 3:20 AM Number of Views: 19 | Item Owner : medhealthinsight Contact Email: (None) Contact Phone: (None) |
Friendly reminder: Click here to read some tips. |